mFOLFOXIRI

Phase 3Small molecule

DDominik Paul Modest

mFOLFOXIRI is one of 103 small molecule programs targeting Colon Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

102

Competitors

Pipeline

Status by Indication[3][1]

Indication

Colon CancerNot yet recruiting

Metastatic Colorectal CancerRecruiting

Colorectal CancerNot yet recruiting

Colon CancerPhase 3

Not yet recruiting

Metastatic Colorectal CancerPhase 3

Recruiting

Colorectal CancerPhase 3

Not yet recruiting

Competition

Competitive Landscape

268 competitors in Colorectal Cancer

#DrugCompanyPhaseTrials

Stivarga

Bayer

Phase 3

39 2

Camptosar

Pfizer

Phase 3

34 3

Wellcovorin

GGlaxo Dba Glaxosmithkline

Phase 3

37 4

Bayer Aspirin

Bayer

Phase 3

7 5

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

8 6

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

3 7

Mitosol

UUroGen Pharma Ltd.

Phase 3

1 8

Botensilimab

AAgenus Inc.

Phase 3

10 9

mFOLFOXIRI

DDominik Paul Modest

Phase 3

3 10

Leucovorin and 5-FU

AAkeso

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 3Not yet recruiting

Colorectal Cancer

NCT05427669

Phase 2Recruiting

Colorectal Cancer

NCT05571644

Q4 2030

Phase 3Recruiting

Metastatic Colorectal Cancer

NCT05008809

Q2 2035

Phase 3Not yet recruiting

Colon Cancer

NCT06899477

Clinical

Trials by Indication[1]

Colorectal Cancer3 trials

Adjuvant mFOLFOXIRI vs. mFOLFOX6 in MRD Positive Stage II-III Colorectal Cancer (AFFORD)

Not yet recruiting·YYanhong Deng·Phase 3·NCT05427669·340 enrolled

Neoadjuvant Treatment With mFOLFOXIRI Plus Cadonilimab (AK104) Versus mFOLFOX6 in Locally Advanced Colorectal Cancer

Recruiting·SSun Yat-sen University·Phase 2·NCT05571644·143 enrolled

mFOLFOXIRI Compared to mFOLFOX6 or CapeOx as Adjuvant Chemotherapy for Stage IIIB or IIIC Colorectal Cancer

Unknown status·FFirst Affiliated Hospital of Wenzhou Medical University·Phase 2·NCT05200299·100 enrolled

Metastatic Colorectal Cancer2 trials

Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418)

Recruiting·DDominik Paul Modest·Phase 3·NCT05008809·507 enrolled

Study of 5-fluorouracil (5-FU) in Patients With Metastatic Colorectal Cancer

Withdrawn·IInova Health Care Services·Phase 2·NCT06501989

Colon Cancer1 trial

Pre-Operative Treatment in REseCTable COlon CanceR

Not yet recruiting·DDominik Paul Modest·Phase 3·NCT06899477·714 enrolled

Cholangiocarcinoma1 trial

Neoadjuvant mFOLFOXIRI for Potentially Resectable Cholangiocarcinoma

Unknown status·KKhon Kaen University·Phase 2·NCT03603834·25 enrolled

Neoadjuvant1 trial

A Trial of Neoadjuvant mFOLFOXIRI Versus CRT in the EMVI Positive LARC

Unknown status·FFirst Affiliated Hospital of Zhejiang University·Phase 2·NCT04423965·220 enrolled

1 more indication

Locally-advanced Rectal Cancer1 trial

Neoadjuvant mFOLFOXIRI Chemotherapy Alone for Extramural Vascular Invasion Positive Locally Advanced Rectal Cancer

Unknown status·FFirst Affiliated Hospital of Zhejiang University·Phase 2·NCT04170530·51 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for mFOLFOXIRI. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — mFOLFOXIRI compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for mFOLFOXIRI. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Dominik Paul Modest company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: DDominik Paul Modest

mFOLFOXIRI

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2030

Q2 2035

Trials by Indication[1]

Colorectal Cancer3 trials

Metastatic Colorectal Cancer2 trials

Colon Cancer1 trial

Cholangiocarcinoma1 trial

Neoadjuvant1 trial

Locally-advanced Rectal Cancer1 trial

References

Drug Info

Quick Facts

Related News